JP2019516720A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516720A5
JP2019516720A5 JP2018560597A JP2018560597A JP2019516720A5 JP 2019516720 A5 JP2019516720 A5 JP 2019516720A5 JP 2018560597 A JP2018560597 A JP 2018560597A JP 2018560597 A JP2018560597 A JP 2018560597A JP 2019516720 A5 JP2019516720 A5 JP 2019516720A5
Authority
JP
Japan
Prior art keywords
compound
general formula
group
ethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516720A (ja
JP7034093B2 (ja
Filing date
Publication date
Priority claimed from GBGB1608777.7A external-priority patent/GB201608777D0/en
Application filed filed Critical
Publication of JP2019516720A publication Critical patent/JP2019516720A/ja
Publication of JP2019516720A5 publication Critical patent/JP2019516720A5/ja
Application granted granted Critical
Publication of JP7034093B2 publication Critical patent/JP7034093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560597A 2016-05-18 2017-05-18 胆汁酸誘導体、特に、オベチコール酸の合成のための中間体 Active JP7034093B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608777.7 2016-05-18
GBGB1608777.7A GB201608777D0 (en) 2016-05-18 2016-05-18 Compounds
PCT/GB2017/051385 WO2017199033A1 (en) 2016-05-18 2017-05-18 Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid

Publications (3)

Publication Number Publication Date
JP2019516720A JP2019516720A (ja) 2019-06-20
JP2019516720A5 true JP2019516720A5 (OSRAM) 2020-07-02
JP7034093B2 JP7034093B2 (ja) 2022-03-11

Family

ID=56320629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560597A Active JP7034093B2 (ja) 2016-05-18 2017-05-18 胆汁酸誘導体、特に、オベチコール酸の合成のための中間体

Country Status (15)

Country Link
US (2) US10968250B2 (OSRAM)
EP (2) EP3458469B1 (OSRAM)
JP (1) JP7034093B2 (OSRAM)
KR (1) KR102458265B1 (OSRAM)
CN (1) CN109415407B (OSRAM)
AU (1) AU2017266539B2 (OSRAM)
CA (1) CA3024281A1 (OSRAM)
EA (1) EA037584B1 (OSRAM)
ES (2) ES2970336T3 (OSRAM)
GB (1) GB201608777D0 (OSRAM)
HR (1) HRP20211128T1 (OSRAM)
HU (1) HUE054851T2 (OSRAM)
MX (1) MX378591B (OSRAM)
PT (1) PT3458469T (OSRAM)
WO (1) WO2017199033A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
EP3431486A1 (en) * 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111138509B (zh) * 2018-11-02 2022-12-06 东莞东阳光药物研发有限公司 奥贝胆酸的制备方法
CN111072744B (zh) * 2019-12-03 2021-09-14 江苏佳尔科药业集团股份有限公司 一种以ba为原料合成熊去氧胆酸的方法
CN114315945A (zh) * 2020-09-28 2022-04-12 四川澄华生物科技有限公司 一种胆甾酸及其衍生物的除杂方法
CN112341516B (zh) * 2020-11-14 2022-07-15 湖南科瑞生物制药股份有限公司 5,6-环氧类固醇类化合物及其制备方法和应用
ES2978497R1 (es) * 2021-11-02 2025-11-03 Sandhill One Llc UDCA de origen no animal de alta pureza

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
WO1994019366A1 (en) 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
KR100948532B1 (ko) 2001-11-07 2010-03-23 넥타르 테라퓨틱스 분지형 중합체 및 그의 공액체
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
CN101374854A (zh) * 2006-01-12 2009-02-25 三菱化学株式会社 甾类化合物的制备方法
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
CA2928178C (en) 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
ES2592452T3 (es) 2008-11-19 2016-11-30 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y métodos de uso de los mismos
AU2009316566B9 (en) 2008-11-19 2014-05-15 Intercept Pharmaceuticals, Inc. TGR5 modulators and method of use thereof
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
WO2014066819A1 (en) 2012-10-26 2014-05-01 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
KR102106186B1 (ko) 2012-11-28 2020-05-04 인터셉트 파마슈티컬즈, 인크. 폐 질환의 치료
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
HRP20180931T1 (hr) 2013-05-14 2018-10-05 Intercept Pharmaceuticals, Inc. 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x
RU2015155552A (ru) 2013-05-24 2017-06-27 Нестек С.А. Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
ES2938874T3 (es) 2014-05-29 2023-04-17 Bar Pharmaceuticals S R L Derivados de colano para su uso en el tratamiento y/o prevención de enfermedades mediadas por FXR y TGR5/GPBAR1
CA2966885A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
TWI686400B (zh) * 2014-11-19 2020-03-01 英商Nzp英國有限公司 化合物(二)
MX375863B (es) 2014-11-19 2025-03-07 Nzp Uk Ltd Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
EA033603B1 (ru) 2014-11-19 2019-11-08 Nzp Uk Ltd 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
HK1244708A1 (zh) 2014-11-26 2018-08-17 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
PL3310801T3 (pl) 2015-06-19 2021-11-22 Intercept Pharmaceuticals, Inc. Modulatory tgr5 i sposoby ich stosowania
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二(叔丁基二甲基硅基氧基)‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技(武汉)有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608779D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds

Similar Documents

Publication Publication Date Title
JP2019516720A5 (OSRAM)
CA2666098C (en) Preparation of nucleosides ribofuranosyl pyrimidines
JP2003528828A5 (OSRAM)
RU2017114156A (ru) N-ацетилгалактозаминовые (galnac) фосфорамитиды, их конъюгаты с нуклеиновыми кислотами и их применение
JP2007513170A5 (OSRAM)
JP2007530450A5 (OSRAM)
JPH11315072A5 (OSRAM)
JP2010500343A5 (OSRAM)
JP2019516717A5 (OSRAM)
JP2017534669A5 (OSRAM)
JP2019516729A5 (OSRAM)
EP0818460A2 (de) Festphasensynthese von Oligonucleotiden
RU2301229C2 (ru) Способ получения производных 2-(6-замещенной-1,3-диоксан-4-ил)-уксусной кислоты
JP2018502174A5 (OSRAM)
JP2012532894A5 (OSRAM)
KR960703937A (ko) 고체 지지체상에서 핵산을 합성하는 방법 및 이 방법에서 고체 지지체로서 유용한 화합물(process for solid support nucleic acid synthesis and compounds useful as solid supports in said process)
RU2223958C2 (ru) Новый способ получения ингибитора протеазы
SI2576565T1 (en) Synthesis of carbanucleoside and its new useful intermediates
ATE475653T1 (de) Verfahren zur herstellung von valsartan
RU97112894A (ru) Производные 10-деацетил-14бета-гидроксибаккатина iii, способ их получения и композиции, содержащие эти соединения
RU2003114754A (ru) Способ получения бисбензазолиловых соединений
Schrempp et al. Synthesis of α‐Chiral Butyrolactones by Highly Stereoselective Radical Transfer or Sequential Asymmetric Alkylations: Concise Preparation of Leupyrrin Moieties
KR870007167A (ko) 페닐 나프티리딘의 제조방법
JP2004115455A5 (OSRAM)
JP2017218460A (ja) 放射ヨウ素標識された3−フルオロプロピル−NOR−β−CITの調製